Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, Jiangsu, China.
Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Sci Rep. 2024 Aug 31;14(1):20267. doi: 10.1038/s41598-024-71318-1.
Bone marrow-derived mesenchymal stem cells (BMSCs) are capable of developing into osteoblastic cell lines in vitro and regenerating bone tissue in vivo, and they are considered to be a reliable source for bone regenerative medicine. In recent years, studies have shown that the immune microenvironment is important for osteogenesis, in which macrophages are an important component of innate immunity and coordinate with stem cells. Metformin (Met), a hypoglycemic drug that exerts a powerful effect on metabolic signaling, has been shown to modulate inflammatory responses and osteogenic activity. However, whether metformin modulates macrophage polarization and subsequently affects osteogenesis remains to be elucidated. In the present study, we investigated the potential immunomodulatory capacity of metformin on macrophage inflammatory responses and phenotypic switching, and the subsequent effects on osteogenic differentiation of BMSCs. Flow cytometry and qPCR were used to study the effects of metformin on macrophage phenotypic regulation. qPCR, ALP, ARS and calcium content measurement and ALP activity assay were used to determine the effects of macrophage-secreted activators on the osteogenic differentiation of BMSCs. Our study demonstrates that metformin can improve the immune microenvironment by modulating macrophage polarization towards an anti-inflammatory phenotype, promoting an increase in a range of anti-inflammatory factors and inhibiting pro-inflammatory factors. This was characterized by increased expression of IL-10 and CD206, Arg-1 and decreased expression of IL-1β, TNF-α, IL-6 and iNOS. In addition, metformin-modulated macrophage-conditioned medium promoted osteogenic differentiation of BMSCs, increased the expression levels of genes (ALP, Runx-2, OCN, and Col-1), enhanced ALP activity, and significantly formed mineralized nodules. In conclusion, our new study elucidates that metformin can promote osteogenic differentiation of BMSCs by modulating macrophage phenotype and thereby.
骨髓间充质干细胞(BMSCs)在体外能向成骨细胞系分化,在体内能再生骨组织,被认为是骨再生医学的可靠来源。近年来的研究表明,免疫微环境对成骨至关重要,其中巨噬细胞是固有免疫的重要组成部分,与干细胞协同作用。二甲双胍(Met)是一种对代谢信号具有强大作用的降血糖药物,已被证明能调节炎症反应和成骨活性。然而,二甲双胍是否调节巨噬细胞极化,进而影响成骨,仍有待阐明。在本研究中,我们研究了二甲双胍对巨噬细胞炎症反应和表型转换的潜在免疫调节作用,以及随后对 BMSCs 成骨分化的影响。流式细胞术和 qPCR 用于研究二甲双胍对巨噬细胞表型调节的影响。qPCR、ALP、ARS 和钙含量测定以及 ALP 活性测定用于确定巨噬细胞分泌的激活剂对 BMSCs 成骨分化的影响。我们的研究表明,二甲双胍可以通过调节巨噬细胞向抗炎表型极化来改善免疫微环境,促进一系列抗炎因子的增加,抑制促炎因子。其特征在于增加 IL-10 和 CD206、Arg-1 的表达,减少 IL-1β、TNF-α、IL-6 和 iNOS 的表达。此外,二甲双胍调节的巨噬细胞条件培养基促进了 BMSCs 的成骨分化,增加了基因(ALP、Runx-2、OCN 和 Col-1)的表达水平,增强了 ALP 活性,并显著形成矿化结节。总之,我们的新研究阐明了二甲双胍通过调节巨噬细胞表型来促进 BMSCs 的成骨分化。